The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial - Top-Institutions - MDSpire

The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial

  • By

  • Alba Solera-Sanchez

  • Hayley Marriott

  • Stanley Windsor

  • Kim Straun

  • Marie A. Neu

  • Elias Dreismickenbecker

  • Francesca Lanfranconi

  • Linda Peli

  • Joachim Wiskemann

  • Nikolai Bauer

  • Filippo Spreafico

  • William Zardo

  • Tobias Baader

  • Peter Wright

  • Joerg Faber

  • Eila Watson

  • on behalf of the FORTEe Consortium

  • July 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    UK centre
    UK centre

    Nottingham, England

    Key Differentiators

    • Pediatric Oncology

  • #2

    FORTEe trial
    FORTEe trial

    N/A, N/A

    Key Differentiators

    • Pediatric Oncology

  • #3

    Italian centres
    Italian centres

    N/A, N/A

    Key Differentiators

    • Pediatric Oncology

  • #4

    German centres
    German centres

    N/A, N/A

    Key Differentiators

    • Pediatric Oncology

Original Source(s)

The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial

  • by Alba Solera-Sanchez, Hayley Marriott, Stanley Windsor, Kim Straun, Marie A. Neu, Elias Dreismickenbecker, Francesca Lanfranconi, Linda Peli, Joachim Wiskemann, Nikolai Bauer, Filippo Spreafico, William Zardo, Tobias Baader, Peter Wright, Joerg Faber, Eila Watson, on behalf of the FORTEe Consortium

  • July 8, 2026

Related Content

Bryan Johnson’s chronic disease is notoriously difficult to diagnose

Case Report: A case of incidentally discovered isolated gastric plasmacytoma

Interpretable early mortality prediction in oncology ICU patients: A dual-cohort validation of a LASSO–XGBoost–SHAP framework